Pheast Therapeutics has received fast track designation from the U.S. Food and Drug Administration (FDA) for PHST001, its candidate treatment for ovarian cancer, a type…
Gynecological cancer
Gynecological cancer encompasses a group of cancers affecting the female reproductive system. Approximately 100,000 people are diagnosed with gynecological cancer in the U.S. every year. Although each type of gynecological cancer is unique, with its own symptoms, risk factors, and treatment options, reaching an early diagnosis is critical for ensuring the best possible outcomes in any of them.
There are several treatment approaches for gynecological cancer, which encompasses all cancers that originate in the female reproductive system. The choice of treatment will depend on the cancer type, how far it has spread, a patient’s general health status, and other factors, such as whether the patient wishes for their fertility to be preserved.
News
GYNECOLOGICAL CANCER
Pembrolizumab improves survival outcomes in ovarian cancer trial
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…
GYNECOLOGICAL CANCER
Testosterone in gender-affirming care doesn’t raise cancer risk
The use of testosterone as part of gender-affirming care does not increase the risk of gynecological cancers in transgender men or gender-diverse people, a study…
GYNECOLOGICAL CANCER
World Ovarian Cancer Day to be observed May 8
Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.
GYNECOLOGICAL CANCER
Tepylute for breast, ovarian cancer launched in US
Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the…
GYNECOLOGICAL CANCER
Provider genetic testing may raise gynecological cancer testing rates
Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with gynecological cancers who underwent testing. That’s…


